EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Acute declines in kidney function with thiazide plus loop diuretics versus loop diuretics alone in acute decompensated heart failure

Wendy McCallum, Hocine Tighiouart, Marcelle Tuttle, Tatsufumi Oka, Tavleen Kaur, Jesús Casado, Jose Luís Morales-Rull, Francesc Formiga iD, Luís Manzano, Jeffrey M Testani, Mark J Sarnak, Joan Carles Trullás

Nephrology Dialysis Transplantation · 30.10.2026 · 41 (11) · 2019-2026

DOI: 10.1093/ndt/gfag070 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nephrology Dialysis Transplantation, online erschienen am 23.03.2026. Verfasst von Wendy McCallum und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Tufts Medical Center, Boston, MA, USA. Hauptthemen laut MEDLINE: Heart Failure, Sodium Potassium Chloride Symporter Inhibitors, Sodium Chloride Symporter Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: NIDDK NIH HHS, Spanish Society of Internal Medicine, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis The association between acute declines in estimated glomerular filtration rate (eGFR) among individuals admitted for acute decompensated heart failure (ADHF) and cardiovascular outcomes has been inconsistent. Our objective was to examine whether eGFR decline and the timing of these declines are associated with mortality and a composite outcome of mortality or heart failure (HF) hospitalization.

Methods

We used data from the CLOROTIC trial, which randomized patients admitted for ADHF to thiazide versus placebo. We examined % eGFR change at 2 days (n = 225) and at 4 days (n = 218) after randomization. Multivariable Cox models were used to evaluate the association between % eGFR change and a primary outcome of mortality and secondary outcome of composite of mortality or HF hospitalization.

Results

Median % eGFR change was -9.7% (IQR -22.1, 5.4) and -14.4% (-25.1, 7.8) in the thiazide arm at 2 and 4 days, respectively, compared to -0.3% (-7.5, 10.1) and 0% (-10.0, 16.2) in the placebo arm at 2 and 4 days, respectively. Over a median 3-month follow-up, of those with 2-day eGFR change available, 41 (18%) patients died and 98 (44%) met the composite outcome, and of those with 4-day eGFR change available, 38 (17.4%) died and 95 (43.6%) met the composite outcome. The eGFR decline at 2 days was not associated with risk of mortality (hazard ratio [HR] = 0.96 [95% CI 0.47, 1.97] and HR = 0.89 [0.37, 2.10] per 30% eGFR decline in the thiazide and placebo arms, respectively). The eGFR decline at 4 days was not associated with risk of mortality in the thiazide arm (HR = 0.86 [0.48, 1.55] per 30% eGFR decline) nor in the placebo (HR = 1.63 [0.82, 3.26] per 30% eGFR decline). Associations were similar for the composite outcome.

Conclusions

Among patients admitted for ADHF and randomized to thiazide versus placebo, early acute declines in eGFR had no association with increased risk of cardiovascular outcomes. Registration Clinicaltrials.gov: NCT01647932; EudraCT Number: 2013-001852-36.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureSodium Potassium Chloride Symporter InhibitorsSodium Chloride Symporter InhibitorsHumansGlomerular Filtration RateFemaleMaleAgedAcute DiseasePrognosisFollow-Up StudiesMiddle AgedKidney Function TestsDrug Therapy, CombinationSurvival RateHospitalization

Stichwörter der Autor:innen

acute decompensated heart failureacute eGFR declinecardiorenal syndromethiazide

Substanzen

Sodium Potassium Chloride Symporter InhibitorsSodium Chloride Symporter Inhibitors

Autor:innen und Institutionen

  • Division of Nephrology, Tufts Medical Center, Boston, MA, USA.
  • Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.
  • Tufts Clinical and Translational Science Institute, Tufts University, Boston, MA, USA.
  • Department of Nephrology, Osaka University Graduate School of Medicine, Suita, Japan.
  • Internal Medicine Department, Hospital Universitario de Getafe, Getafe, Madrid, Spain.
  • Heart Failure Unit, Internal Medicine Department, Hospital Universitari Arnau de Villanova, Institut de Recerca Biomédica (IRBLleida), Lleida, Spain.

ORCID-Profile: Francesc Formiga

Förderung

  • NIDDK NIH HHS
  • Spanish Society of Internal Medicine
  • NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institutes of Health

Zitieren

APA

McCallum, W., Tighiouart, H., Tuttle, M., Oka, T., Kaur, T., Casado, J., Morales-Rull, J. L., Formiga, F., Manzano, L., Testani, J. M., Sarnak, M. J., & Trullás, J. C. (2026). Acute declines in kidney function with thiazide plus loop diuretics versus loop diuretics alone in acute decompensated heart failure. Nephrology Dialysis Transplantation, 41(11), 2019-2026. https://doi.org/10.1093/ndt/gfag070

Vancouver

McCallum W, Tighiouart H, Tuttle M, Oka T, Kaur T, Casado J, et al. Acute declines in kidney function with thiazide plus loop diuretics versus loop diuretics alone in acute decompensated heart failure. Nephrology Dialysis Transplantation. 2026;41(11):2019-2026. doi:10.1093/ndt/gfag070

BibTeX
@article{McCallum2026,
  author = {McCallum, Wendy and Tighiouart, Hocine and Tuttle, Marcelle and Oka, Tatsufumi and Kaur, Tavleen and Casado, Jesús and Morales-Rull, Jose Luís and Formiga, Francesc and Manzano, Luís and Testani, Jeffrey M and Sarnak, Mark J and Trullás, Joan Carles},
  title = {Acute declines in kidney function with thiazide plus loop diuretics versus loop diuretics alone in acute decompensated heart failure},
  journal = {Nephrology Dialysis Transplantation},
  year = {2026},
  volume = {41},
  number = {11},
  pages = {2019--2026},
  doi = {10.1093/ndt/gfag070}
}
Kostenlos starten →